index	sentence	Gene	Mutation	prediction
0	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Leu19Phe	1
1	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Lys117Asn	1
2	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Ala146Thr	1
3	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Arg164Gln	1
4	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Lys117Asn	1
5	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Ala146Thr	1
6	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Leu19Phe	1
7	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Arg164Gln	1
8	Ras proteins regulate signal transduction by activating a number of downstream effector proteins, including the cytoplasmic serine/threonine protein kinase B-Raf (Figure 1)	 protein kinase B-Raf	serine/threonine	0
9	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A	0
10	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid	1
11	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E	1
12	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A	0
13	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid	1
14	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E	1
15	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V	0
16	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D	0
17	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D	0
18	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H	0
19	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F	0
20	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N	0
21	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T	0
22	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q	0
23	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V	0
24	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D	0
25	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D	0
26	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H	0
27	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F	0
28	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N	0
29	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T	0
30	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q	1
31	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V	0
32	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D	0
33	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D	0
34	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H	0
35	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F	0
36	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N	0
37	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T	0
38	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q	1
39	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V	1
40	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D	1
41	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D	1
42	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H	0
43	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F	1
44	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N	1
45	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T	1
46	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q	1
47	500 mug of cell lysate from each sample was incubated with 10 mug of Raf-1 RBD agarose at 4 C for 30 min with gentle rocking	Raf-1	C for 30	1
48	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V	1
49	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D	1
50	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C	1
51	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D	1
52	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H	0
53	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F	1
54	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N	1
55	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T	1
56	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q	1
57	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V	1
58	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D	1
59	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C	1
60	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D	1
61	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H	0
62	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F	1
63	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N	1
64	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T	1
65	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q	1
66	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5	1
67	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5	1
68	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	G57T	1
69	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	Leu19Phe	0
70	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	V600E	0
71	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	K-Ras	V600E	1
72	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	B-Raf	V600E	1
73	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V	1
74	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D	1
75	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D	0
76	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H	1
77	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F	1
78	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N	0
79	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T	0
80	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q	0
81	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V	1
82	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D	1
83	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D	0
84	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H	1
85	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F	1
86	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N	0
87	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T	0
88	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q	0
89	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V	1
90	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D	1
91	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D	1
92	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H	1
93	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F	1
94	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N	1
95	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T	0
96	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q	0
97	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	G12V	1
98	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	L19F	1
99	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	K117N	1
100	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	A146T	1
101	In contrast, the R164Q mutation, like wt K-Ras, was not GTP-bound.	K-Ras	R164Q	1
102	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	K117N	1
103	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	A146T	1
104	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q	1
105	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q	1
106	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Ptpre	R164Q	1
107	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Arhgap6	R164Q	1
108	RFLP analysis of B-Raf V599E mutation	Raf	V599E	1
109	The B-Raf V599E mutation was detected using a novel RFLP assay, where the presence of the mutation destroyed a recognition site for the restriction enzyme TspRI	Raf	V599E	1
110	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E	1
111	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E	1
112	Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation	HRAS	p.Lys117Arg	1
113	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	L19F	1
114	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	K117N	1
115	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	A146T	1
116	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	R164Q	1
117	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	G12V	1
118	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V	1
119	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V	1
